Cargando…

Pharmacological and Toxicological Threshold of Bisammonium Tetrakis 4-(N,N-Dimethylamino)pyridinium Decavanadate in a Rat Model of Metabolic Syndrome and Insulin Resistance

Vanadium(IV/V) compounds have been studied as possible metallopharmaceutical drugs against diabetes mellitus. However, mechanisms of action and toxicological threshold have been tackled poorly so far. In this paper, our purposes were to evaluate the metabolic activity on dyslipidemia and dysglycemia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Treviño, Samuel, Díaz, Alfonso, Sánchez-Lara, Eduardo, Sarmiento-Ortega, Víctor Enrique, Flores-Hernández, José Ángel, Brambila, Eduardo, Meléndez, Francisco J., González-Vergara, Enrique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031092/ https://www.ncbi.nlm.nih.gov/pubmed/30026756 http://dx.doi.org/10.1155/2018/2151079

Ejemplares similares

Metforminium Decavanadate as a Potential Metallopharmaceutical Drug for the Treatment of Diabetes Mellitus
por: Treviño, Samuel, et al.
Publicado: (2016)

Tetrakis(2,6-dimethylpyridinium) dihydrogen decavanadate dihydrate
por: Rakovský, Erik, et al.
Publicado: (2014)

Bis[4-(dimethylamino)pyridinium] bis[4-(dimethylamino)pyridine-κN (1)]tetrakis(thiocyanato-κN)manganate(II)
por: Wöhlert, Susanne, et al.
Publicado: (2012)

Decavanadate Salts of Cytosine and Metformin: A Combined Experimental-Theoretical Study of Potential Metallodrugs Against Diabetes and Cancer
por: Sánchez-Lara, Eduardo, et al.
Publicado: (2018)

Crystal structures of bis[4-(dimethylamino)pyridinium] tetrakis(thiocyanato-κN)manganate(II) and tris[4-(dimethylamino)pyridinium] pentakis(thiocyanato-κN)manganate(II)
por: Neumann, Tristan, et al.
Publicado: (2018)

Pancreas–Liver–Adipose Axis: Target of Environmental Cadmium Exposure Linked to Metabolic Diseases
por: Moroni-González, Diana, et al.
Publicado: (2023)

4-(Dimethylamino)pyridinium trichlorido[4-(dimethylamino)pyridine-κN]cobaltate(II)
por: Guenifa, Fatiha, et al.
Publicado: (2013)

Decavanadate Toxicology and Pharmacological Activities: V(10) or V(1), Both or None?
por: Aureliano, M.
Publicado: (2016)

Pyridinium bis(pyridine-κN)tetrakis(thiocyanato-κN)ferrate(III)
por: Shylin, Sergii I., et al.
Publicado: (2013)

Hepatic Insulin Resistance Model in the Male Wistar Rat Using Exogenous Insulin Glargine Administration
por: Sarmiento-Ortega, Victor Enrique, et al.
Publicado: (2023)

4-(Dimethylamino)pyridinium dibromidotriphenylstannate(IV)
por: Norhafiza, Ilyana, et al.
Publicado: (2008)

Redetermination of 4-(dimethylamino)pyridinium tribromide
por: Ng, Seik Weng
Publicado: (2010)

4-(Dimethylamino)pyridinium 4-toluenesulfonate
por: McAdam, C. John, et al.
Publicado: (2008)

Bis[4-(dimethylamino)pyridinium] tetrachloridozincate
por: Kefi, Riadh, et al.
Publicado: (2011)

4-(Dimethylamino)pyridinium tetrachloridoferrate(III)
por: Khadri, Amina, et al.
Publicado: (2013)

Tris(2-Pyridylmethylamine)V(O)(2) Complexes as Counter Ions of Diprotonated Decavanadate Anion: Potential Antineoplastic Activity
por: Corona-Motolinia, Nidia D., et al.
Publicado: (2022)

Tris[4-(dimethylamino)pyridinium] hexakis(thiocyanato-κN)ferrate(III) monohydrate
por: Wöhlert, Susanne, et al.
Publicado: (2012)

Solution- and gas-phase study of binding of ammonium and bisammonium hydrocarbons to oxacalix[4]arene carboxylate
por: Cowart, Anna, et al.
Publicado: (2023)

Tetrakis[μ-4-(dimethylamino)benzoato-κ(2) O:O′]bis[(N,N-diethylnicotinamide-κN (1))zinc(II)]
por: Hökelek, Tuncer, et al.
Publicado: (2009)

Bis[4-(dimethylamino)pyridinium] pentabromidochloridostannate(IV)
por: Jang, Yong, et al.
Publicado: (2009)

Bis[4-(dimethylamino)pyridinium] tetrabromidocobaltate(II)
por: Lo, Kong Mun, et al.
Publicado: (2009)

Bis[4-(dimethylamino)pyridinium] tetrabromidocuprate(II)
por: Lo, Kong Mun, et al.
Publicado: (2009)

Bis[4-(dimethylamino)pyridinium] tribromidochloridodimethylstannate(IV)
por: Lo, Kong Mun, et al.
Publicado: (2008)

Bis[4-(dimethylamino)pyridinium] dibromidodichloridodimethylstannate(IV)
por: Lo, Kong Mun, et al.
Publicado: (2008)

4-(Dimethylamino)pyridinium tribromido{3-[bromo/hydro(0.9/0.1)]-4-(dimethylamino)pyridine-κN (1)}cobaltate(II)
por: Lo, Kong Mun, et al.
Publicado: (2009)

Nonapiperidinium monohydrogen decavanadate tetranitrate
por: Graia, Mohsen, et al.
Publicado: (2009)

4-(Dimethylamino)pyridinium tetrachlorido(quinoline-2-carboxylato-κ(2) N,O)stannate(IV)
por: Najafi, Ezzatollah, et al.
Publicado: (2011)

4-(Dimethylamino)pyridinium tetrachlorido(pyridine-2-carboxylato-κ(2) N,O)stannate(IV)
por: Najafi, Ezzatollah, et al.
Publicado: (2012)

Bis[4-(dimethylamino)pyridinium] tetrabromidodiphenylplumbate(IV)
por: Lo, Kong Mun, et al.
Publicado: (2008)

Bis[4-(dimethylamino)pyridinium] tetrabromidodiphenylstannate(IV)
por: Yap, Quai Ling, et al.
Publicado: (2008)

Bis[4-(dimethylamino)pyridinium] tetrabromidocadmate(II) monohydrate
por: Lo, Kong Mun, et al.
Publicado: (2009)

The NOAEL Metformin Dose Is Ineffective against Metabolic Disruption Induced by Chronic Cadmium Exposure in Wistar Rats
por: Sarmiento-Ortega, Victor Enrique, et al.
Publicado: (2018)

Clinical monitored in subjects metabolically healthy and unhealthy before and during a SARS-CoV-2 infection– A cross-sectional study in Mexican population
por: Treviño, Samuel, et al.
Publicado: (2022)

Bis[4-(dimethylamino)pyridinium] tetrachloridocuprate(II)
por: Bouacida, Sofiane, et al.
Publicado: (2013)

Pyridinium bis(pyridine-κN)tetrakis(thiocyanato-κN)ferrate(III)–pyrazine-2-carbonitrile–pyridine (1/4/1)
por: Shylin, Sergii I., et al.
Publicado: (2013)

Tetrakis(μ-4-methylbenzoato-κO:O′)bis{[4-(dimethylamino)pyridine-κN (1)]zinc(II)}
por: Bai, Lin-Shan, et al.
Publicado: (2009)

Tetrakis(μ-benzoato-κ(2) O:O′)bis{[4-(dimethylamino)pyridine-κN (1)]zinc(II)}
por: Yu, Zhe-Yin, et al.
Publicado: (2011)

N,N,N′,N′-Tetrakis(2-hydroxyethyl)terephthalamide
por: Wang, Zhi-Qiang, et al.
Publicado: (2008)

Hexakis(tetraaquasodium) decavanadate(V) dihydrate
por: Nilsson, Jessica, et al.
Publicado: (2010)

2-(2-Pyridyl)pyridinium (2,2′-bipyridine-κ(2) N,N′)tetrakis(nitrato-κ(2) O,O′)bismuthate(III)
por: Meng, Zhao-Hui, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_vb7e2s0067e96a29ml0cjdmtm2